```
FILE 'MEDLINE, EMBASE, USPATFULL, BIOSIS, CAPLUS' ENTERED AT 13:35:25 ON
25 JUN 2003
L1        1326 S (TGF-BETA)(2A) RELATED
L2         999 S L1 AND PY<2001
L3         219 S L2 (S) HOMOLOG?
L4         149 DUP REM L3 (70 DUPLICATES REMOVED)
```

L Number	Hits	Search Text	DB	Time stamp
1	6140	TGF adj beta	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/25 13:19
2	266	(TGF adj beta) NEAR2 RELATED	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/25 13:19

CC   The invention relates to an anti-viral mammalian transforming growth
CC   factor beta-10 (Ztgfbeta-10) polypeptide and polynucleotides encoding it.
CC   The Ztgfbeta-10 polypeptide can be expressed by standard recombinant
CC   methodology. The Ztgfbeta-10 is useful to regulate the proliferation,
CC   differentiation and apoptosis of neurons, glial cells, lymphocytes,
CC   haematopoietic cells and stromal cells, and to raise antibodies that bind
CC   to the polypeptide. The Ztgfbeta-10 polypeptides, antibodies or anti-
CC   idiotypic antibodies are useful for treating conditions associated with
CC   abnormal physiology or development, including abnormal proliferation,
CC   e.g., cancerous conditions or degenerative conditions, and to treat
CC   inflammation. The Ztgfbeta-10 polynucleotides are useful in gene therapy
CC   to treat human diseases such as cancer, immune and autoimmune diseases,
CC   and diseases of the central and peripheral nervous system. The present

CC   sequence represents a cDNA encoding the human Ztgfbeta-10 polypeptide.
XX
SQ   Sequence 639 BP; 145 A; 173 C; 161 G; 160 T; 0 other;

   Query Match   60.3%;   Score 401.2;   DB 24;   Length 639;
   Best Local Similarity 96.9%;   Pred. No. 5.5e-121;
   Matches 409; Conservative   0; Mismatches   13; Indels   0; Gaps   0;

Qy   81 TGGTTTTACCCTCATATTCAAAAAAACCCTTAATCTCTAATGTGGAGCAGCTGATCCTGG 140
          || || | | ||| | ||||||||||||||||||||||||||||||||||||
Db   218 TGTTTCACCTGCCTTATGTCCAGAAACCCTTAATCTCTAATGTGGAGCAGCTGATCCTGG 277

Qy   141 GGATCCCGGGCCAGAATCGCCGGGAGATAGGCCATGGCCAGGATATCTTTCCAGCAGAGA 200
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   278 GGATCCCGGGCCAGAATCGCCGGGAGATAGGCCATGGCCAGGATATCTTTCCAGCAGAGA 337

Qy   201 AGCTCTGCCATCTGCAGGATCGCAAGGTGAACCTTCACAGAGCTGCCTGGGGCGAGTGTA 260
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   338 AGCTCTGCCATCTGCAGGATCGCAAGGTGAACCTTCACAGAGCTGCCTGGGGCGAGTGTA 397

Qy   261 TTGTTGCACCCAAGACTCTCAGCTTCTCTTACTGTCAGGGGACCTGCCCGGCCCTCAACA 320
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   398 TTGTTGCACCCAAGACTCTCAGCTTCTCTTACTGTCAGGGGACCTGCCCGGCCCTCAACA 457

Qy   321 GTGAGCTCCGTCATTCCAGCTTTGAGTGCTATAAGAGGGCAGTACCTACCTGTCCCTGGC 380
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   458 GTGAGCTCCGTCATTCCAGCTTTGAGTGCTATAAGAGGGCAGTACCTACCTGTCCCTGGC 517

Qy   381 TCTTCCAGACCTGCCGTCCCACCATGGTCAGACTCTTCTCCCTGATGGTCCAGGATGACG 440
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   518 TCTTCCAGACCTGCCGTCCCACCATGGTCAGACTCTTCTCCCTGATGGTCCAGGATGACG 577

Qy   441 AACACAAGATGAGTGTGCACTATGTGAACACTTCCTTGGTGGAGAAGTGTGGCTGCTCTT 500
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   578 AACACAAGATGAGTGTGCACTATGTGAACACTTCCTTGGTGGAGAAGTGTGGCTGCTCTT 637

Qy   501 GA 502
          ||
Db   638 GA 639